Amgen 3Q

Amgen 3Q09

3Q Revenues: $3.8 billion (flat)

3Q Earnings: $1.4 billion (+23%)

YTD Revenues: $10.8 billion (-4%)

YTD Earnings: $3.7 billion (+17%)

Comments: Product sales fell 1% in 3Q09 to $3.7 billion; U.S. sales were flat at $2.9 billion. Enbrel sales climbed 3% to $924 million, with a price increase offsetting a drop in unit sales in dermatology. Aranesp sales fell 19% to $685 million in the quarter, while Epogen rose 5% to $663 million. Neulasta and Neupogen sales grew 2% to $1.2 billion. For YTD, Enbrel sales are -4% at $2.6 billion.

Read Amgen’s profile in this year’s Top 10 Biopharmas Report!